UPC CFI 382/2025
Apr 29, 2025·EP2501384 +1 more: METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
- Case details
- StatusCase ClosedActionGenericCategoryCosts Assessments
- Parties
- Division
- Milan CD
- Technology
- Organic Chemistry
- Language
- English
- 2025-07-31Costs onlyApplication For Costs
Decision on costs from the Milan Central Division dated 31 July 2025 in proceedings where Novartis AG sought reimbursement of costs from Zentiva K.S. and Zentiva Portugal Lda following the dismissal of Zentiva's revocation action against EP 2 501 384. The court dismissed Novartis' costs application because Novartis failed to comply with the court's request under R. 156.1 RoP to provide substantiated evidence of costs (itemised hourly rates and hours), instead providing only a sworn general statement. The court held that: (1) once a R. 156.1 request is issued, costs can no longer be assessed equitably but only on proof; (2) confidentiality cannot be invoked to withhold cost information from the court; (3) costs for legal representation are not per se confidential under R. 262A RoP.
Legal issues:Standard of proof for cost reimbursement after R. 156.1 RoP requestConfidentiality of legal cost informationEquitable assessment of costs versus proof-based assessment
| Document title | Date | Public |
|---|---|---|
| Case Closure Formal Check | 2025-08-20 | Not public |
| Headnote-and-Keywords | 2025-07-31 | Not public |
| Application-For-Costs-Decision-Outcome | 2025-07-31 | Not public |
| DECISION | 2025-07-31 | Public |
| 20250609 Cost recovery observations No 2 pdf a signee | 2025-06-09 | Not public |
| 20250609 Cost recovery observations No 2 pdf a signee | 2025-06-09 | Not public |
| 2025 06 03 - Comments on Submission by Zentiva | 2025-06-03 | Not public |
| Outcome of the Order | 2025-06-03 | Not public |
| ORDER 3 JUNE | 2025-06-03 | Public |
| ORDER 3 JUNE | 2025-06-03 | Public |
| ORDER 29 MAY | 2025-05-29 | Not public |
| PC005 UPC - Code of Conduct for Representatives | 2025-05-27 | Not public |
| PC006 Email from Schertenleib to Bristows | 2025-05-27 | Not public |
| 20250527 Cost recovery observations v def PDFA certifie | 2025-05-27 | Not public |
| PC008 EC Press Release Commission Fines Teva 462 6 Million for Abusing Patent System to Delay MS Drug Competition | 2025-05-27 | Not public |
| PC007 UPC Milan CD 23 December 2024 Insulet v Menarini Procedural Order UPC CFI 3802024 EN | 2025-05-27 | Not public |
| PC002 CJEU 28 April 2022 Case C 53120 NovaText GmbH v Ruprecht Karls Universitat Heidelberg Opinion Advocate General | 2025-05-27 | Not public |
| PC001 CJEU 28 April 2022 Case C 53120 NovaText GmbH v Ruprecht Karls Universitat Heidelberg Judgement | 2025-05-27 | Not public |
| PC003 UPC Milan LD 9 May 2025 Oerlikon Textile GmbH Co KG v Bhagat Textile Engineers Case CFI 7612024 Proc No 639922024 | 2025-05-27 | Not public |
| PC003 UPC Milan LD 9 May 2025 Oerlikon Textile GmbH Co KG v Bhagat Textile Engineers Case CFI 7612024 Proc No 639922024 | 2025-05-27 | Not public |
| PC004 Attestation from Marc Lauzeral | 2025-05-27 | Not public |
| PC003 UPC Milan LD 9 May 2025 Oerlikon Textile GmbH Co KG v Bhagat Textile Engineers Case CFI 7612024 Proc No 639922024 | 2025-05-27 | Not public |
| PC008 EC Press Release Commission Fines Teva 462 6 Million for Abusing Patent System to Delay MS Drug Competition | 2025-05-27 | Not public |
| PC002 CJEU 28 April 2022 Case C 53120 NovaText GmbH v Ruprecht Karls Universitat Heidelberg Opinion Advocate General | 2025-05-27 | Not public |
| PC001 CJEU 28 April 2022 Case C 53120 NovaText GmbH v Ruprecht Karls Universitat Heidelberg Judgement | 2025-05-27 | Not public |
| 20250527 Cost recovery observations v def PDFA certifie | 2025-05-27 | Not public |
| PC003 UPC Milan LD 9 May 2025 Oerlikon Textile GmbH Co KG v Bhagat Textile Engineers Case CFI 7612024 Proc No 639922024 | 2025-05-27 | Not public |
| PC005 UPC - Code of Conduct for Representatives | 2025-05-27 | Not public |
| PC007 UPC Milan CD 23 December 2024 Insulet v Menarini Procedural Order UPC CFI 3802024 EN | 2025-05-27 | Not public |
| PC004 Attestation from Marc Lauzeral | 2025-05-27 | Not public |
| PC006 Email from Schertenleib to Bristows | 2025-05-27 | Not public |
| Application pursuant to Rule 262A RoP | 2025-05-23 | Not public |
| Outcome of the Order | 2025-05-20 | Not public |
| ORDER 20 MAY | 2025-05-20 | Public |
| ORDER 20 MAY | 2025-05-20 | Public |
| Template-Order | 2025-05-20 | Not public |
| ORDER | 2025-05-20 | Not public |
| 20250519 Cost recovery observation vdef | 2025-05-19 | Not public |
| 20250519 deadline extension vdef | 2025-05-19 | Not public |
| 20250519 deadline extension vdef | 2025-05-19 | Not public |
| ORDER 15 MAY | 2025-05-15 | Not public |
| Application pursuant to Rule 262A RoP | 2025-05-13 | Not public |
| Application pursuant to Rule 262A RoP | 2025-05-13 | Not public |
| Annex A - CONFIDENTIAL Annex A to Declaration of Yvonne Madawela - 13 May 2025 | 2025-05-13 | Not public |
| Comments on costs claimed | 2025-05-13 | Not public |
| Annex 3 - Declaration of Yvonne Madawela - 13 May 2025 | 2025-05-13 | Not public |
| Annex A - CONFIDENTIAL Annex A to Declaration of Yvonne Madawela - 13 May 2025 | 2025-05-13 | Not public |
| ORDER 6 MAY SIGNED | 2025-05-06 | Public |
| ORDER 6 MAY | 2025-05-06 | Public |
| Request for confirmation | 2025-05-06 | Not public |
| Request for confirmation | 2025-05-05 | Not public |
| 2025 05 02 - Request for extension-signed | 2025-05-02 | Not public |
| ORDER 29 APRIL 2025 | 2025-04-29 | Not public |
| Template-Order | 2025-04-29 | Not public |
| Panel-Appointment | 2025-04-29 | Not public |
| Receipt | 2025-04-29 | Not public |
| Acknowledgement-of-lodging | 2025-04-28 | Not public |
| Annex 1 | 2025-04-28 | Not public |
| Annex 2 | 2025-04-28 | Not public |
| 2025 04 28 - Application for a cost decision Novartis-signed | 2025-04-28 | Not public |